A citation-based method for searching scientific literature


List of co-cited articles
657 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity





A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C Prinz, Yasmine Wasfi, Shu Li, Yaung-Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich. N Engl J Med 2015
208
60

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Howard Sofen, Stacy Smith, Robert T Matheson, Craig L Leonardi, Cesar Calderon, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J Marciniak, Yasmine Wasfi,[...]. J Allergy Clin Immunol 2014
193
56


First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Yanli Zhuang, Cesar Calderon, Stanley J Marciniak, Esther Bouman-Thio, Philippe Szapary, Tong-Yuan Yang, Allen Schantz, Hugh M Davis, Honghui Zhou, Zhenhua Xu. Eur J Clin Pharmacol 2016
51
40

Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Tadashi Terui, Satomi Kobayashi, Yukari Okubo, Masamoto Murakami, Keiichiro Hirose, Hiroshi Kubo. JAMA Dermatol 2018
55
36

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, Anish Mehta, Nicole Cichanowitz, Qing Li,[...]. Lancet 2017
288
36

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Kim A Papp, Richard G Langley, Mark Lebwohl, Gerald G Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li,[...]. Lancet 2008
32

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring,[...]. N Engl J Med 2017
295
32

Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database.
Kiyoshi Kubota, Yukari Kamijima, Tsugumichi Sato, Nobuhiro Ooba, Daisuke Koide, Hajime Iizuka, Hidemi Nakagawa. BMJ Open 2015
150
28

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
28

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
James G Krueger, Laura K Ferris, Alan Menter, Frank Wagner, Alexander White, Sudha Visvanathan, Bojan Lalovic, Stella Aslanyan, Elaine E L Wang, David Hall,[...]. J Allergy Clin Immunol 2015
170
28

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
K Papp, D Thaçi, K Reich, E Riedl, R G Langley, J G Krueger, A B Gottlieb, H Nakagawa, E P Bowman, A Mehta,[...]. Br J Dermatol 2015
185
28

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G Krueger, Richard G Langley, Craig Leonardi, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Lisa T Dooley, Mark Lebwohl. N Engl J Med 2007
592
28

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley,[...]. Lancet 2018
278
28


Clinical improvement in psoriasis with specific targeting of interleukin-23.
Tamara Kopp, Elisabeth Riedl, Christine Bangert, Edward P Bowman, Elli Greisenegger, Ann Horowitz, Harald Kittler, Wendy M Blumenschein, Terrill K McClanahan, Thomas Marbury,[...]. Nature 2015
152
24

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
K Reich, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, A B Kimball. Br J Dermatol 2019
41
24

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
150
24

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
Laura K Ferris, Elyssa Ott, Jingzhi Jiang, H Chih-Ho Hong, Shu Li, Chenglong Han, Wojciech Baran. J Dermatolog Treat 2020
21
28

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
495
24


Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi,[...]. J Dermatol Sci 2011
148
24



Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
128
24

Pathogenesis and clinical features of psoriasis.
Christopher Em Griffiths, Jonathan Nwn Barker. Lancet 2007
20

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
803
20

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt. J Drugs Dermatol 2018
28
20

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia. Lancet 2018
103
20


Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Peter Foley, Kenneth Gordon, Christopher E M Griffiths, Yasmine Wasfi, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt. JAMA Dermatol 2018
46
20


Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Mark Lebwohl, Craig Leonardi, Christopher E M Griffiths, Jörg C Prinz, Philippe O Szapary, Newman Yeilding, Cynthia Guzzo, Shu Li, Ming-Chun Hsu, Bruce Strober. J Am Acad Dermatol 2012
79
20

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.
A Blauvelt, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaçi, Q Li, N Cichanowitz,[...]. Br J Dermatol 2018
40
20

Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
Nehal N Mehta, Daniel B Shin, Aditya A Joshi, Amit K Dey, April W Armstrong, Kristina Callis Duffin, Zelma Chiesa Fuxench, Charlotte L Harrington, Rebecca A Hubbard, Robert E Kalb,[...]. Circ Cardiovasc Imaging 2018
91
20


Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
A B Kimball, K A Papp, Y Wasfi, D Chan, R Bissonnette, H Sofen, N Yeilding, S Li, P Szapary, K B Gordon. J Eur Acad Dermatol Venereol 2013
129
20


Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Tadashi Terui, Satomi Kobayashi, Yukari Okubo, Masamoto Murakami, Richuan Zheng, Hitomi Morishima, Ryosuke Goto, Takayuki Kimura. JAMA Dermatol 2019
37
20

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams,[...]. Lancet 2019
116
20

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Mamitaro Ohtsuki, Hideki Fujita, Mitsunori Watanabe, Keiko Suzaki, Mary Flack, Xin Huang, Susumu Kitamura, Joaquin Valdes, Atsuyuki Igarashi. J Dermatol 2019
43
20


Pustulosis palmoplantaris is a disease distinct from psoriasis.
Anne C de Waal, Peter C M van de Kerkhof. J Dermatolog Treat 2011
54
16

Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum.
Masamoto Murakami, Eva Hagforsen, Vera Morhenn, Akemi Ishida-Yamamoto, Hajime Iizuka. Exp Dermatol 2011
68
16

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
Alice Gottlieb, John Sullivan, Martijn van Doorn, Alexey Kubanov, Ruquan You, Anne Parneix, Sophie Hugot, Marina Milutinovic. J Am Acad Dermatol 2017
77
16


Psoriasis causes as much disability as other major medical diseases.
S R Rapp, S R Feldman, M L Exum, A B Fleischer, D M Reboussin. J Am Acad Dermatol 1999
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.